Technical Description
The invention introduces a novel anticoagulant formulation, known as Pegylated Dabigatran (PEG-DAB), offers improved pharmacokinetics and pharmacodynamics. It effectively prevents blood clot formation, reducing the risk of stroke and other complications. Notably, PEG-DAB also alleviates neurological deficits.
Problems Addressed
- Poor Aqueous Solubility
- Limited Bioavailability
- Non-specific Uptake
- Adverse Side Effects
- Requires High Doses
Tech Features
- Pegylated Anticoagulant Formulation
- Elevates Neurological Deficit
- Increased Aqueous Solubility
- Enhanced Anti-thrombotic Activity
- Enhanced Absorption
- Enhanced Stability
- High Bioavailability
- High Production Yield
Target Audience
- Pharmaceutical Industry
- Healthcare Industry
- Hospitals and Clinics
- Biotechnology Industry
- Clinical Research Industry
Tech ID: P27-1210 TRL 4 Patent Status: Granted Available For Exclusive and Non-exclusive License
